Metrion Biosciences (“Metrion”), the specialist preclinical contract analysis group (CRO) and a pacesetter in ion channel screening, as we speak introduced the appointment of Lee Patterson as its new CEO, efficient from 2nd December 2024. An skilled life sciences and CRO govt, Lee will information the Firm because it seeks to execute an bold progress technique, enhancing its specialist companies and increasing additional in key international markets. He succeeds Dr Andrew Southan, who has determined to step down as CEO after 5 years within the put up.
A famend chief within the sector, Lee Patterson makes a speciality of steering preclinical CROs to implement sturdy and efficient plans for long-term business progress. Beforehand CEO at Charnwood Discovery, a supplier of built-in drug discovery companies with a worldwide biotech and pharma consumer base, he led the corporate via its profitable acquisition by Idea Life Sciences in October 2024. Previous to this, Lee served as Chief Working Officer at Quanticate, a worldwide biometrics CRO, and Chief Working Officer at Idea Life Sciences. He additionally held a number of govt roles at Covance/Labcorp, the latest being Govt Director, World Operations and Early Growth Administration Workplace.
Lee will be a part of lately appointed CCO Dr Chris Mathes as the newest addition to Metrion’s senior management crew1. Working intently alongside Chris and the broader administration crew, Lee’s C-suite stage experience and expertise will assist Metrion to bolster its international business presence and scientific capabilities.
Outgoing CEO Dr Andrew Southan has led Metrion efficiently since 2019, greater than doubling revenues over that point and overseeing the Firm’s progress in staffing, laboratory amenities and worldwide consumer base. He additionally led the Firm’s profitable £3.7M fairness financing spherical in December 2023.
On behalf of the Board and administration crew, I wish to thank Andy Southan for his devoted management during the last 5 years, specifically establishing Metrion’s repute as a top quality, specialist CRO and a number one heart of experience in ion channel biology. On the similar time, I’m delighted to welcome Lee Patterson to the Firm. His expertise of main business CROs and his experience in enhancing operational efficiencies are each excellent and we look ahead to working with him to proceed Metrion’s progress as a specialist CRO serving international markets.”
Keith McCullagh, Chairman, Metrion Biosciences
Lee Patterson, CEO, Metrion Biosciences, commented: “Metrion Biosciences has constructed a powerful repute in ion channel drug discovery, with confirmed dedication to excellent customer support and world class science. I’m excited to hitch this gifted crew and look ahead to working with them to reinforce and broaden our specialised companies to satisfy the wants of our shoppers worldwide.”
